10821811

FILE 'HOME' ENTERED AT 17:04:33 ON 26 FEB 2009

=> file reg
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 0.22 0.22

FILE 'REGISTRY' ENTERED AT 17:04:47 ON 26 FEB 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 25 FEB 2009 HIGHEST RN 1111946-16-7
DICTIONARY FILE UPDATES: 25 FEB 2009 HIGHEST RN 1111946-16-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> s methylnaltrexone/cn
L1 1 METHYLNALTREXONE/CN

=> d l1

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2009 ACS on STN
RN 73232-52-7 REGISTRY
ED Entered STN: 16 Nov 1984
CN Morphinanium, 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-17-methyl-6-
oxo-, bromide, (5α)- (CA INDEX NAME)
OTHER NAMES:
CN **Methylnaltrexone**
CN Methylnaltrexone bromide
CN MRZ 2663BR
CN N-Cyclopropylmethyl-noroxymorphone methobromide
CN N-Methylnaltrexone bromide
CN Naltrexone methobromide
CN Naltrexone methyl bromide
FS STEREOSEARCH
MF C21 H26 N O4 . Br
LC STN Files: ADISNEWS, BIOSIS, BIOTECHNO, CA, CAPLUS, CASREACT, CBNB, CIN,
DDFU, DRUGU, EMBASE, IMSDRUGNEWS, IMSPATENTS, IMSRESEARCH, IPA, PROMT,
PROUSDDR, RTECS*, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL
(*File contains numerically searchable property data)
CRN (83387-25-1)

Absolute stereochemistry.

Jagoe

10821811



● Br^-

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

141 REFERENCES IN FILE CA (1907 TO DATE)
6 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
141 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> file medicine
FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	7.88	8.10

FILE 'ADISCTI' ENTERED AT 17:05:29 ON 26 FEB 2009
COPYRIGHT (C) 2009 Adis Data Information BV

FILE 'ADISINSIGHT' ENTERED AT 17:05:29 ON 26 FEB 2009
COPYRIGHT (C) 2009 Adis Data Information BV

FILE 'ADISNEWS' ENTERED AT 17:05:29 ON 26 FEB 2009
COPYRIGHT (C) 2009 Adis Data Information BV

FILE 'BIOSIS' ENTERED AT 17:05:29 ON 26 FEB 2009
Copyright (c) 2009 The Thomson Corporation

FILE 'BIOTECHNO' ENTERED AT 17:05:29 ON 26 FEB 2009
COPYRIGHT (C) 2009 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'CAPLUS' ENTERED AT 17:05:29 ON 26 FEB 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'DDFB' ENTERED AT 17:05:29 ON 26 FEB 2009
COPYRIGHT (C) 2009 THOMSON REUTERS

Jagoe

10821811

FILE 'DDFU' ACCESS NOT AUTHORIZED

FILE 'DGENE' ENTERED AT 17:05:29 ON 26 FEB 2009

FILE 'DISSABS' ENTERED AT 17:05:29 ON 26 FEB 2009

FILE 'DRUGB' ENTERED AT 17:05:29 ON 26 FEB 2009

FILE 'DRUGMONOG2' ENTERED AT 17:05:29 ON 26 FEB 2009

FILE 'DRUGU' ENTERED AT 17:05:29 ON 26 FEB 2009

FILE 'EMBAL' ENTERED AT 17:05:29 ON 26 FEB 2009

FILE 'EMBASE' ENTERED AT 17:05:29 ON 26 FEB 2009

FILE 'ESBIOBASE' ENTERED AT 17:05:29 ON 26 FEB 2009

FILE 'IFIPAT' ENTERED AT 17:05:29 ON 26 FEB 2009

FILE 'IMSDRUGNEWS' ENTERED AT 17:05:29 ON 26 FEB 2009

FILE 'IMSPRODUCT' ENTERED AT 17:05:29 ON 26 FEB 2009

FILE 'IPA' ENTERED AT 17:05:29 ON 26 FEB 2009

FILE 'KOSMET' ENTERED AT 17:05:29 ON 26 FEB 2009

FILE 'LIFESCI' ENTERED AT 17:05:29 ON 26 FEB 2009

FILE 'MEDLINE' ENTERED AT 17:05:29 ON 26 FEB 2009

FILE 'NAPRALERT' ENTERED AT 17:05:29 ON 26 FEB 2009

FILE 'NLDB' ENTERED AT 17:05:29 ON 26 FEB 2009

FILE 'NUTRACEUT' ENTERED AT 17:05:29 ON 26 FEB 2009

FILE 'PASCAL' ENTERED AT 17:05:29 ON 26 FEB 2009

Jagoe

FILE 'PCTGEN' ENTERED AT 17:05:29 ON 26 FEB 2009

FILE 'PHARMAML' ENTERED AT 17:05:29 ON 26 FEB 2009

FILE 'PHIN' ENTERED AT 17:05:29 ON 26 FEB 2009

FILE 'SCISEARCH' ENTERED AT 17:05:29 ON 26 FEB 2009

FILE 'TOXCENTER' ENTERED AT 17:05:29 ON 26 FEB 2009

FILE 'USGENE' ENTERED AT 17:05:29 ON 26 FEB 2009

FILE 'USPATFULL' ENTERED AT 17:05:29 ON 26 FEB 2009

FILE 'USPATOLD' ENTERED AT 17:05:29 ON 26 FEB 2009

FILE 'USPAT2' ENTERED AT 17:05:29 ON 26 FEB 2009


```
=> s l1
'CN' IS NOT A VALID FIELD CODE
'CN' IS NOT A VALID FIELD CODE
'CN' IS NOT A VALID FIELD CODE
'CN' IS NOT A VALID FIELD CODE
'CN' IS NOT A VALID FIELD CODE
'CN' IS NOT A VALID FIELD CODE
'CN' IS NOT A VALID FIELD CODE
'CN' IS NOT A VALID FIELD CODE
'CN' IS NOT A VALID FIELD CODE
'CN' IS NOT A VALID FIELD CODE
'CN' IS NOT A VALID FIELD CODE
'CN' IS NOT A VALID FIELD CODE
'CN' IS NOT A VALID FIELD CODE
'CN' IS NOT A VALID FIELD CODE
'CN' IS NOT A VALID FIELD CODE
L2         472 L1

=> s solution
  33 FILES SEARCHED...
L3     7560721 SOLUTION

=> 's l1 and l2

'S IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> s l1 and l2
'CN' IS NOT A VALID FIELD CODE
```

Jagoe

10821811

'CN' IS NOT A VALID FIELD CODE
'CN' IS NOT A VALID FIELD CODE
'CN' IS NOT A VALID FIELD CODE
'CN' IS NOT A VALID FIELD CODE
'CN' IS NOT A VALID FIELD CODE
'CN' IS NOT A VALID FIELD CODE
'CN' IS NOT A VALID FIELD CODE
'CN' IS NOT A VALID FIELD CODE
'CN' IS NOT A VALID FIELD CODE
'CN' IS NOT A VALID FIELD CODE
'CN' IS NOT A VALID FIELD CODE
'CN' IS NOT A VALID FIELD CODE
'CN' IS NOT A VALID FIELD CODE
L4 472 L1 AND L2

=> s l2 and l3
L5 49 L2 AND L3

=> s pH
L6 7717984 PH

=> s chelat?
L7 666798 CHELAT?

=> s l5 and l6 and l7
L8 8 L5 AND L6 AND L7

=> dup rem
ENTER L# LIST OR (END):l8
DUPLICATE IS NOT AVAILABLE IN 'ADISINSIGHT, ADISNEWS, DGENE, DRUGMONOG2,
IMSPRODUCT, KOSMET, NUTRACEUT, PCTGEN, PHARMAML, USGENE'.
ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE
PROCESSING COMPLETED FOR L8
L9 8 DUP REM L8 (0 DUPLICATES REMOVED)

=> s l9 and pd<2004
5 FILES SEARCHED...
'2004' NOT A VALID FIELD CODE
'2004' NOT A VALID FIELD CODE
'2004' NOT A VALID FIELD CODE
14 FILES SEARCHED...
16 FILES SEARCHED...
'2004' NOT A VALID FIELD CODE
22 FILES SEARCHED...
'2004' NOT A VALID FIELD CODE
27 FILES SEARCHED...
'2004' NOT A VALID FIELD CODE
31 FILES SEARCHED...
L10 0 L9 AND PD<2004

=> s EDTA or dipotassium edetate or disodium etetate or edetate calcium disodium or sodium
edetate or trisodium edetate or potassium edetate
21 FILES SEARCHED...
33 FILES SEARCHED...
L11 451335 EDTA OR DIPOTASSIUM EDETATE OR DISODIUM ETETATE OR EDETATE CALCI
UM DISODIUM OR SODIUM EDETATE OR TRISODIUM EDETATE OR POTASSIUM
EDETATE

=> s l5 and l11

Jagoe

L12 16 L5 AND L11

=> dup rem
ENTER L# LIST OR (END):l12
DUPLICATE IS NOT AVAILABLE IN 'ADISINSIGHT, ADISNEWS, DGENE, DRUGMONOG2,
IMSPRODUCT, KOSMET, NUTRACEUT, PCTGEN, PHARMAML, USGENE'.
ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE
PROCESSING COMPLETED FOR L12
L13 16 DUP REM L12 (0 DUPLICATES REMOVED)

=> s l13 and pd<2004
5 FILES SEARCHED...
'2004' NOT A VALID FIELD CODE
'2004' NOT A VALID FIELD CODE
'2004' NOT A VALID FIELD CODE
14 FILES SEARCHED...
16 FILES SEARCHED...
'2004' NOT A VALID FIELD CODE
22 FILES SEARCHED...
'2004' NOT A VALID FIELD CODE
27 FILES SEARCHED...
'2004' NOT A VALID FIELD CODE
31 FILES SEARCHED...
L14 1 L13 AND PD<2004

=> d l14 ibib, kwic

L14 ANSWER 1 OF 1 USPATFULL on STN
ACCESSION NUMBER: 2003:30960 USPATFULL
TITLE: Use of methylnaltrexone to treat immune suppression
INVENTOR(S): Moss, Jonathan, Chicago, IL, UNITED STATES
Yuan, Chun-Su, Chicago, IL, UNITED STATES
PATENT ASSIGNEE(S): University of Chicago, Chicago, IL (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 20030022909	A1	20030130	<--
APPLICATION INFO.:	US 2002-163482	A1	20020605 (10)	

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-295571P	20010605 (60)
	US 2002-374454P	20020422 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Chantal Morgan D'Apuzzo, Wolf, Greenfield & Sacks,
P.C., 600 Atlantic Ave., Boston, MA, 02210
NUMBER OF CLAIMS: 81
EXEMPLARY CLAIM: 1
LINE COUNT: 1407
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

SUMM . . . Methylnaltrexone is available in a powder form from
Mallinckrodt Pharmaceuticals, St. Louis, Mo. Methylnaltrexone can be
prepared as a sterile **solution** at a concentration of 5 mg/ml.
Methylnaltrexone can also be administered as an oral agent in a capsule
or tablet or in an oral **solution**.
DETD [0089] Blood is drawn from the arm catheter used for methylnaltrexone
injection into **EDTA** Vacutainers prelabeled with the study
number, subject number and initials, dose number, date, time of sample,

at the times indicated. . .
IT **73232-52-7**, Methylnaltrexone
(peripheral opioid antagonists such as methylnaltrexone to treat opioid-induced immune suppression)

```
=> dup rem
ENTER L# LIST OR (END):l5
DUPLICATE IS NOT AVAILABLE IN 'ADISINSIGHT, ADISNEWS, DGENE, DRUGMONOG2,
IMSPRODUCT, KOSMET, NUTRACEUT, PCTGEN, PHARMAML, USGENE'.
ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE
PROCESSING COMPLETED FOR L5
L15          45 DUP REM L5 (4 DUPLICATES REMOVED)

=> s l15 and pd<2004
   5 FILES SEARCHED...
'2004' NOT A VALID FIELD CODE
'2004' NOT A VALID FIELD CODE
'2004' NOT A VALID FIELD CODE
  14 FILES SEARCHED...
  16 FILES SEARCHED...
'2004' NOT A VALID FIELD CODE
  22 FILES SEARCHED...
'2004' NOT A VALID FIELD CODE
  27 FILES SEARCHED...
'2004' NOT A VALID FIELD CODE
  31 FILES SEARCHED...
L16          3 L15 AND PD<2004

=> d l16 1-3 ibib, kwic

L16  ANSWER 1 OF 3  USPATFULL on STN
ACCESSION NUMBER:       2003:30960  USPATFULL
TITLE:                  Use of methylnaltrexone to treat immune suppression
INVENTOR(S):            Moss, Jonathan, Chicago, IL, UNITED STATES
                        Yuan, Chun-Su, Chicago, IL, UNITED STATES
PATENT ASSIGNEE(S):     University of Chicago, Chicago, IL (U.S. corporation)

                             NUMBER       KIND    DATE
                        ---------------- ------ --------
PATENT INFORMATION:     US 20030022909     A1   20030130            <--
APPLICATION INFO.:      US 2002-163482     A1   20020605  (10)

                               NUMBER        DATE
                        ------------------ --------
PRIORITY INFORMATION:   US 2001-295571P    20010605 (60)
                        US 2002-374454P    20020422 (60)
DOCUMENT TYPE:          Utility
FILE SEGMENT:           APPLICATION
LEGAL REPRESENTATIVE:   Chantal Morgan D'Apuzzo, Wolf, Greenfield & Sacks,
                        P.C., 600 Atlantic Ave., Boston, MA, 02210
NUMBER OF CLAIMS:       81
EXEMPLARY CLAIM:        1
LINE COUNT:             1407
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

SUMM   . . .  Methylnaltrexone is available in a powder form from
       Mallinckrodt Pharmaceuticals, St. Louis, Mo. Methylnaltrexone can be
       prepared as a sterile solution at a concentration of 5 mg/ml.
       Methylnaltrexone can also be administered as an oral agent in a capsule
```

or tablet or in an oral **solution**.
IT **73232-52-7**, Methylnaltrexone
(peripheral opioid antagonists such as methylnaltrexone to treat opioid-induced immune suppression)

L16 ANSWER 2 OF 3 USPATFULL on STN

ACCESSION NUMBER:	1998:115766 USPATFULL			
TITLE:	Pharmaceutical compositions comprising an opiate antagonist and calcium salts, their use for the treatment of endorphin-mediated pathologies			
INVENTOR(S):	Minoia, Paolo, Via M. Viterbo 12, I-70013 Castellana Grotte, (Bari), Italy Sciorsci, Raffaele Luigi, Via Positano, 84/B, I-70014 Conversano, (Bari), Italy			
	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5811451		19980922	<--
	WO 9531985		19951130	<--
APPLICATION INFO.:	US 1996-737902		19961121	(8)
	WO 1995-EP1931		19950522	
			19961121	PCT 371 date
			19961121	PCT 102(e) date
	NUMBER		DATE	
PRIORITY INFORMATION:	IT 1994-MI1048		19940524	
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	Granted			
PRIMARY EXAMINER:	MacMillan, Keith D.			
LEGAL REPRESENTATIVE:	Bucknam and Archer			
NUMBER OF CLAIMS:	17			
EXEMPLARY CLAIM:	1			
LINE COUNT:	464			

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

DETD The administration of 5 mg of naloxone dissolved in a **solution** of 50 g of calcium gluconate in 500 ml of sterile water in one cow affected by the above mentioned. . .

DETD 40 dogs affected by parvovirus gastroenteritis were treated i.v. daily with a sterile aqueous **solution** containing naloxone (0.5-1 mg), calcium gluconate (0.5 g), vitamin C (500-1000 mg), vitamin K (1 g).

IT 50-81-7, Vitamin C, biological studies 125-73-5, Dextrorphan 137-08-6, Calcium pantothenate 299-28-5, Calcium gluconate 465-65-6, Naloxone 591-64-0, Calcium levulinate 814-80-2, Calcium lactate 2520-36-7, Ficine 5001-51-4, Calcium lactobionate 5743-27-1, Calcium ascorbate 5743-34-0, Calcium borogluconate 6384-92-5 7440-70-2D, Calcium, salts 9001-00-7, Bromelin 9001-01-8, Callicrein 9001-09-6, Chymopapain 9001-12-1, Collagenase 9001-73-4, Papaine 9001-75-6, Pepsin 9001-92-7, Protease 9002-07-7, Trypsin 9004-06-2, Elastase 9004-07-3, Chymotrypsin 9014-01-1, Subtilisin 9028-00-6, Clostripain 12001-79-5, Vitamin K 14357-78-9, Diprenorphine 16590-41-3, Naltrexone 17673-25-5, Phorbol 20123-80-2, Calcium dobesilate 20594-83-6, Nalbuphine 29039-00-7, Calcium glucoheptonate 37228-80-1, Proteinase A 39450-01-6 55096-26-9, Nalmefene 56095-64-8 56649-76-4, MR-2266 71276-43-2, Quadazocine 72782-05-9, β-Funaltrexamine 73232-50-5, Methylnaloxonium **73232-52-7** 73674-85-8, Naloxazone 75684-07-0, Bremazocine 81669-70-7, Metalloendopeptidase 82823-99-2, Naltrexonazine 82824-01-9,

Naloxonazine 89352-67-0, ICI 174864 103429-31-8, CTOP 105618-26-6, Norbinaltorphimine 110881-59-9 111555-53-4, Naltrindole 111555-58-9, Naltriben 126876-64-0, Naltrindole-5'-isothiocyanate 129468-28-6, 7-Benzylidenenaltrexone 136109-04-1, LY 274614
(compns. containing opiate antagonist and calcium salts for treatment of endorphin-mediated disorders in human and veterinary medicine)

L16 ANSWER 3 OF 3 USPATFULL on STN
ACCESSION NUMBER: 79:47543 USPATFULL
TITLE: Quaternary derivatives of noroxymorphone which relieve intestinal immobility
INVENTOR(S): Goldberg, Leon I., Chicago, IL, United States
Merz, Herbert, Ingelheim am Rhein, Germany, Federal Republic of
Stockhaus, Klaus, Bingen, Germany, Federal Republic of
PATENT ASSIGNEE(S): Boehringer Ingelheim GmbH, Ingelheim am Rhein, Germany, Federal Republic of (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4176186		19791127	<--
APPLICATION INFO.:	US 1978-928821		19780728	(5)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Daus, Donald G.
ASSISTANT EXAMINER: Rivers, Diana G.
LEGAL REPRESENTATIVE: Hammond & Littell
NUMBER OF CLAIMS: 4
EXEMPLARY CLAIM: 1,3,4
LINE COUNT: 413
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

DETD An excess of concentrated ammonia was added to a concentrated aqueous **solution** of 18.2 gm (0.05 mol) of N-allyl-noroxymorphone hydrochloride, whereupon the free base precipitated, which was separated by extraction with chloroform.. . . dried with sodium sulfate and evaporated in vacuo. The residue was dissolved in 150 ml of absolute acetone, the resulting **solution** was admixed with 18 ml (0.29 mol) of methyl iodide in a pressure vessel, the vessel was sealed, and the. . .

DETD . . . the free base as described in Example 1. The free base was dissolved in 180 ml of absolute acetone, the **solution** was admixed with 33.0 ml (0.6 mol) of methyl bromide in a pressure vessel, the vessel was sealed, and its. . .

DETD . . . base was dissolved in 40 ml of absolute acetone, 3.8 gm (0.03 mol) of dimethyl sulfate were added to the **solution**, and the mixture was refluxed for 48 hours, during which time an oil gradually separated out. Thereafter, the oil was. . .

DETD . . . (0.0256 mol) of N-allyl-noroxymorphone methoiodide, prepared in accordance with Example 1, were dissolved in 500 ml of water, and the **solution** was filtered through a column charged with a strongly basic anion exchanger (bromide-loaded anion exchanger, 171 gm, with an exchange. . . 70° C. The residue was dissolved in 100 ml of methanol, and 100 ml of ether were added to the **solution**, whereupon 9.65 gm (92% of theory) of the methobromide, m.p. 245° C., separated out. After recrystallization from methanol it had. . .

DETD . . . were dissolved in a mixture consisting of 50 ml of absolute acetone and 0.5 ml of dimethylformamide, and the resulting **solution** was admixed with 4.25 gm (44.8 millimols) of methyl bromide. The reaction mixture was then allowed to stand for three. . .

DETD . . . hydrochloride in Example 1. The free base was dissolved in 50 ml of absolute acetone in a pressure vessel, the **solution** was admixed with 8 ml (0.128 mol) of methyl iodide, the vessel was sealed, and the reaction mixture was heated. . .

DETD . . . millimols) of N-propargyl-noroxymorphone were dissolved in a mixture consisting of 30 ml of methanol and 20 ml of dimethylformamide, the **solution** was admixed with 6.8 gm (71.6 millimols) of methyl bromide, and the mixture was heated at 70° C. in a. . .

DETD . . . methylene chloride, 3.4 gm (0.033 mol) of triethylamine were added and, while cooling the mixture on an ice bath, a **solution** of 2.6 gm (0.033 mol) of acetyl chloride in absolute methylene chloride was admixed therewith. The ice bath was then. . . reaction mixture was slowly allowed to warm to room temperature and was subsequently refluxed for one hour. Thereafter, the reaction **solution** was cooled, washed twice with ice water, dried with sodium sulfate and evaporated in vacuo, leaving as the residue O.sup.3. . .

DETD . . . in analogy to the procedure of Example 2. After a reaction time of seven days at 70° C., the reaction **solution** was evaporated in vacuo, leaving as the residue O.sup.3 -acetyl-N-allyl-noroxymorphone methobromide.

DETD (c) The evaporation residue obtained in step (c) was dissolved in 1 N hydrobromic acid, and the **solution** was evaporated in vacuo on a water bath at 60° C. The residue was crystallized as described in Example 2,. . .

DETD . . . was dissolved in 60 ml of absolute methylene chloride. While stirring and cooling it on an ice bath, the resulting **solution** was admixed with 2.22 gm (0.015 mol) of trimethyloxonium fluoroborate. After 1 hour the ice bath was removed, and the mixture was stirred for sixteen hours at room temperature. Thereafter, the reaction **solution** was evaporated, the residual quaternary fluoroborate was dissolved in 150 ml of water, and the **solution** was filtered, in analogy to Example 2, through a strong basic anion exchange column (175 gm, OH-form, about 0.25 Val), and the column was rinsed with about 1 liter of water. The combined aqueous **solutions** were then acidified with concentrated hydrobrmic acid (pH about 3) and subsequently evaporated in vacuo on a water bath at. . .

DETD . . . mol) of trans-3-chloroallyl chloride and 70 ml of dimethylformamide was stirred for four hours at 90° C. Thereafter, the reaction **solution** was evaporated in vacuo, and the residue was shaken with a mixture of 75 ml of chloroform and 75 ml. . .

DETD The hydrochloride, m.p. 243° C., was obtained by dissolving the base in methanolic hydrochloric acid and adding ether to the **solution** until it just turned cloudy.

DETD . . . hydrochloride, m.p. 202° C., was obtained by dissolving the base in ethanolic hydrochloric acid and adding ether thereto until the **solution** just began to turn cloudy.

DETD . . . inert pharmaceutical carrier and one effective dosage unit of the active ingredient, such as tablets, coated pills, capsules, wafers, powders, **solutions**, suspensions, emulsions, syrups, suppositories and the like. One effective dosage unit of the compounds according to the present invention is. . .

DETD . . . a portion of the inert excipients, and the mixture is granulated in conventional manner with the aid of an aqueous **solution** of the soluble starch. The granulate is then dried and admixed with the remainder of the inert excipients, and the. . .

DETD Hypodermic **solution**

DETD The **solution** is compounded from the following ingredients:

DETD The active ingredient and the sodium chloride are dissolved in the distilled water, the **solution** is filtered until free from

suspended particles, and the filtrate is filled into 5 cc-ampules which are sterilized and sealed.. . .
DETD Drop **solution**
DETD The **solution** is compounded from the following ingredients:
DETD The active ingredient and the p-hydroxy-benzoates (preservatives) are dissolved in the de-mineralized water, the **solution** is filtered, and the filtrate is filled into 100 ml-bottles. 5 ml of the **solution** are an oral dosage unit composition containing 50 mgm of the active ingredient.
IT 73232-44-7P 73232-48-1P 73232-49-2P 73232-51-6P **73232-52-7P**
73232-53-8P 73232-54-9P 73232-56-1P 73246-51-2P
(preparation of)

=> s disodium edetate
L17 4470 DISODIUM EDETATE

=> d his

(FILE 'HOME' ENTERED AT 17:04:33 ON 26 FEB 2009)

FILE 'REGISTRY' ENTERED AT 17:04:47 ON 26 FEB 2009
L1 1 S METHYLNALTREXONE/CN

FILE 'ADISCTI, ADISINSIGHT, ADISNEWS, BIOSIS, BIOTECHNO, CAPLUS, DDFB, DGENE, DISSABS, DRUGB, DRUGMONOG2, DRUGU, EMBAL, EMBASE, ESBIOBASE, IFIPAT, IMSDRUGNEWS, IMSPRODUCT, IPA, KOSMET, LIFESCI, MEDLINE, NAPRALERT, NLDB, NUTRACEUT, PASCAL, PCTGEN, PHARMAML, ...' ENTERED AT 17:05:29 ON 26 FEB 2009
L2 472 S L1
L3 7560721 S SOLUTION
L4 472 S L1 AND L2
L5 49 S L2 AND L3
L6 7717984 S PH
L7 666798 S CHELAT?
L8 8 S L5 AND L6 AND L7
L9 8 DUP REM L8 (0 DUPLICATES REMOVED)
L10 0 S L9 AND PD<2004
L11 451335 S EDTA OR DIPOTASSIUM EDETATE OR DISODIUM ETETATE OR EDETATE CA
L12 16 S L5 AND L11
L13 16 DUP REM L12 (0 DUPLICATES REMOVED)
L14 1 S L13 AND PD<2004
L15 45 DUP REM L5 (4 DUPLICATES REMOVED)
L16 3 S L15 AND PD<2004
L17 4470 S DISODIUM EDETATE

=> s l11 or l17
L18 453892 L11 OR L17

=> s l18 and l2
L19 17 L18 AND L2

=> dup rem
ENTER L# LIST OR (END):l19
DUPLICATE IS NOT AVAILABLE IN 'ADISINSIGHT, ADISNEWS, DGENE, DRUGMONOG2, IMSPRODUCT, KOSMET, NUTRACEUT, PCTGEN, PHARMAML, USGENE'.
ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE
PROCESSING COMPLETED FOR L19
L20 17 DUP REM L19 (0 DUPLICATES REMOVED)

10821811

```
=> s l20 and pd<2004
   5 FILES SEARCHED...
'2004' NOT A VALID FIELD CODE
'2004' NOT A VALID FIELD CODE
'2004' NOT A VALID FIELD CODE
  14 FILES SEARCHED...
  16 FILES SEARCHED...
'2004' NOT A VALID FIELD CODE
  22 FILES SEARCHED...
'2004' NOT A VALID FIELD CODE
  27 FILES SEARCHED...
'2004' NOT A VALID FIELD CODE
  31 FILES SEARCHED...
L21          1 L20 AND PD<2004

=> d l21 ibib, kwic


L21  ANSWER 1 OF 1  USPATFULL on STN
ACCESSION NUMBER:       2003:30960  USPATFULL
TITLE:                  Use of methylnaltrexone to treat immune suppression
INVENTOR(S):            Moss, Jonathan, Chicago, IL, UNITED STATES
                        Yuan, Chun-Su, Chicago, IL, UNITED STATES
PATENT ASSIGNEE(S):     University of Chicago, Chicago, IL (U.S. corporation)

                             NUMBER       KIND    DATE
                        ---------------- ------ --------
PATENT INFORMATION:     US 20030022909     A1   20030130            <--
APPLICATION INFO.:      US 2002-163482     A1   20020605  (10)

                               NUMBER        DATE
                        ------------------ --------
PRIORITY INFORMATION:   US 2001-295571P    20010605 (60)
                        US 2002-374454P    20020422 (60)
DOCUMENT TYPE:          Utility
FILE SEGMENT:           APPLICATION
LEGAL REPRESENTATIVE:   Chantal Morgan D'Apuzzo, Wolf, Greenfield & Sacks,
                        P.C., 600 Atlantic Ave., Boston, MA, 02210
NUMBER OF CLAIMS:       81
EXEMPLARY CLAIM:        1
LINE COUNT:             1407
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

DETD   [0089] Blood is drawn from the arm catheter used for methylnaltrexone
       injection into EDTA Vacutainers prelabeled with the study
       number, subject number and initials, dose number, date, time of sample,
       at the times indicated.  .  .
IT  73232-52-7, Methylnaltrexone
        (peripheral opioid antagonists such as methylnaltrexone to treat
        opioid-induced immune suppression)
```